Interpretation of the new national medical insurance drug catalogue

In the early stage, the National Medical Insurance Bureau held a press conference to introduce the adjustment of the national medical insurance drug catalogue in 2023. This year is the sixth consecutive year that the national medical insurance drug list has been adjusted, and a total of 126 new drugs have been added. Among them, 121 drugs entered the national medical insurance drug list through negotiation or bidding, the most in the past year, with an average price reduction of 61.7%. Covering chronic diseases, rare diseases, children's medicine and other fields, a large number of new mechanisms and new target drugs have been included in the scope of the catalog.

The adjustment of the medical insurance catalogue in 2023 has been slightly adjusted on the basis of previous years' experience. It mainly includes the following three aspects: First, the declaration conditions. According to the rules, the time requirements for drug approval and indication modification have been extended, and drugs approved for marketing or indication modification after January 1, 2018 can submit declarations. At the same time, considering the changes in the epidemic prevention and control situation, the application conditions of novel coronavirus treatment drugs are no longer listed, and such drugs can be declared normally through the conditions. The second is the adjustment procedure. Mainly from the expert review, data template, information and other aspects of optimization. Among them, in terms of evaluation methods, further improve the evaluation indicators, comprehensively consider clinical needs, patient benefits and other factors, and more accurately evaluate the value of drugs to better achieve the goal of "value purchase". Third, strengthen supervision. Further strengthen the supervision and management of enterprise behavior. Gradually establish enterprise credit files, strengthen credit management, and improve joint disciplinary mechanisms. For the violations of laws and regulations, fraud, and other dishonest behaviors of enterprises, after verification, it will be linked to the management of the medical insurance drug catalog according to the circumstances, to achieve linkage, urge enterprises to abide by the law, be honest and trustworthy, fair competition, and maintain the seriousness, standardization, and fairness of medical insurance management.

The 2023 healthcare talks send a signal to encourage innovative drugs and encourage innovative companies. Only innovation is the driving force of pharmaceutical development, so that valuable innovative drugs can get the price that matches their value. First, this round of 23 domestic innovative drugs have been included in the scope of the catalog, which is the most over the years. From the side reflects the national pharmaceutical industry research and development enthusiasm continues to rise, innovation ability continues to enhance. The second is to ensure the basic chronic diseases and common diseases to achieve drug replacement. In 2023, 84 new drugs will be transferred, accounting for 2/3 of the total number of drugs transferred into the catalog. Third, the efforts to promote rare disease drugs into the medical insurance catalogue are greater than in previous years. This year, 15 rare disease drugs have been transferred, involving 16 rare disease types. After 6 years of continuous adjustment, the 75 rare disease drugs currently approved for listing in China have been included in the national medical insurance drug catalog, with an average price reduction of more than 50%.

At present, the national medical insurance drug catalog has achieved "one adjustment a year", and more than 80% of new drugs can be included in the medical insurance within two years of listing, greatly boosting the confidence of the pharmaceutical industry's research and innovation. After this round of adjustment, the total number of drugs in the new medical insurance catalogue has increased to 3,088 (including 1,698 Western medicines and 1,390 proprietary Chinese medicines), covering all areas of clinical treatment, and the level of protection has been further improved. In this round of adjustment, our products Zizo ® -L-carnitine injection and Qiqiong ® -Tropisetron hydrochloride injection cancel the suffix restriction of medical insurance, and the National Medical Insurance Bureau will truly return the right to choose drugs and make decisions to clinicians. Qidu Pharmaceutical focuses on the enterprise and product development plan of "one basic product, ten treatment areas and six business segments". At present, 119 varieties such as Ganxiang ®- Glycerin fructose sodium chloride injection and Diyixin ®- Levofloxacin sodium chloride injection have been selected into the new version of the "Medical Insurance Drug Catalogue". It is expected that more than 10 newly approved products will be included in the medical insurance catalog in 2024.